Publications by authors named "R W Bender"

Challenges in drug development for rare diseases such as pulmonary arterial hypertension can be addressed through the use of mathematical modeling. In this study, a quantitative systems pharmacology model of pulmonary arterial hypertension pathophysiology and pharmacology was used to predict changes in pulmonary vascular resistance and six-minute walk distance in the context of oral treprostinil clinical studies. We generated a virtual population that spanned the range of clinical observations and then calibrated virtual patient-specific weights to match clinical trials.

View Article and Find Full Text PDF

Ovarian-derived estrogen can signal non-canonically at membrane-associated receptors in the brain to rapidly regulate neuronal function. Early alcohol drinking confers greater risk for alcohol use disorder in women than men, and binge alcohol drinking is correlated with high estrogen levels, but a causal role for estrogen in driving alcohol drinking has not been established. We found that female mice displayed greater binge alcohol drinking and reduced avoidance when estrogen was high during the estrous cycle than when it was low.

View Article and Find Full Text PDF
Article Synopsis
  • * Out of 50 Cochrane Reviews analyzed, only 48% provided clear outcome definitions for the time-to-event analyses, and critical trial characteristics related to these analyses were often missing or inaccurately reported.
  • * The inconsistencies in reporting and methods at both the trial and review levels hinder the reliability of meta-analyses on time-to-event outcomes, suggesting a need for improved standards in research reporting.
View Article and Find Full Text PDF

Augmentation of the nasal dorsum often requires implantation of structural material. Existing methods include autologous, cadaveric or alloplastic materials and injectable hydrogels. Each of these options is associated with considerable limitations.

View Article and Find Full Text PDF
Article Synopsis
  • This study focuses on evaluating fezolinetant, a nonhormonal treatment option for vasomotor symptoms (VMS) experienced during menopause, to determine a meaningful threshold for symptom reduction in postmenopausal women.
  • The research pooled data from two phase 3 trials where women were randomized to receive either fezolinetant or a placebo, and their VMS frequency was tracked using electronic diaries alongside a questionnaire assessing symptom change.
  • Results show that a reduction of about six VMS episodes per day is linked with a significant clinical benefit, with higher successful response rates observed in the fezolinetant groups compared to the placebo at both 4 and 12 weeks.
View Article and Find Full Text PDF